Vesper Healthcare Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing November 20, 2020

PR Newswire

MIAMI BEACH, Fla., Nov. 19, 2020 /PRNewswire/ — Vesper Healthcare Acquisition Corp. (NASDAQ: VSPRU) (the “Company”) announced that, commencing November 20, 2020, holders of the units sold in the Company’s initial public offering may elect to separately trade shares of the Company’s Class A common stock and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Class A common stock and warrants that are separated will trade on the NASDAQ Capital Market under the symbols “VSPR” and “VSPRW,” respectively. Those units not separated will continue to trade on the NASDAQ Capital Market under the symbol “VSPRU.”

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Vesper Healthcare Acquisition Corp.

The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.  While the Company may pursue an initial business combination target in any business or industry, it intends to focus its search on companies in the pharmaceutical and healthcare sectors.  Vesper Healthcare is led by Chief Executive Officer, Brent Saunders.

Forward-Looking Statements

This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (“SEC”). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact: 

Manisha Narasimhan, PhD
CFO, Vesper Healthcare Acquisition Corp.
[email protected]        

Cision View original content:http://www.prnewswire.com/news-releases/vesper-healthcare-acquisition-corp-announces-the-separate-trading-of-its-class-a-common-stock-and-warrants-commencing-november-20-2020-301176659.html

SOURCE Vesper Healthcare

Cato Reports 3Q Net Loss

PR Newswire

CHARLOTTE, N.C., Nov. 19, 2020 /PRNewswire/ — The Cato Corporation (NYSE: CATO) today reported a net loss of $3.6 million or ($0.15) per diluted share for the third quarter ended October 31, 2020, compared to net income of $6.0 million or $0.24  per diluted share for the third quarter ended November 2, 2019.  Sales for the third quarter were $149.2 million, or a decrease of 21% from sales of $189.4 million for the third quarter ended November 2, 2019.   The Company’s same-store sales for the quarter decreased 23% to the same period last year.

As previously announced, Cato closed all stores due to the COVID-19 pandemic beginning March 19, 2020.  On May 1, 2020, the Company began reopening stores in a phased approach, with limited operating hours, consistent with local health and safety guidelines and regulations.  As of June 15, 2020, all stores had reopened.

For the nine months ended October 31, 2020, the Company reported a net loss of $39.2 million or ($1.64) per diluted share, compared to net income of $39.1 million or $1.59 per diluted share for the nine months ended November 2, 2019.  Sales for the nine months ended October 31, 2020 were $414.3 million, down 34% to sales of $627.8 million for the nine months ended November 2, 2019.  Year-to-date same-store sales decreased 35%.

“Sales in the third quarter reflected continued softening of customer demand as COVID-19 cases continued to rise throughout our market areas and many people still have not returned to work. As we see this trend continuing, we anticipate that the remainder of the year will be challenging,” stated John Cato, Chairman, President, and Chief Executive Officer. “We appreciate our store associates’ diligence in providing a safe shopping environment and our customers’ patience as we continue our enhanced cleaning and product handling procedures to make our stores as safe as possible in light of the COVID-19 pandemic.”

For the quarter, gross margin decreased to 26.7% from 37.4% of sales the prior year due to a reduction in merchandise contribution, combined with the effects of deleveraging from the sales decline. SG&A expenses as a percent of sales increased to 34.8% from 34.2% during the quarter primarily due to the effects of deleveraging, and an impairment charge of $2.3 million, partially offset by company-wide expense reductions and reduction of incentive compensation compared to prior year. A pre-tax loss and the beneficial effects of the CARES Act resulted in $9.7 million of tax benefit versus $0.1 million of expense in the prior year. The Company ended the quarter with unrestricted cash and short-term investments of $151.4 million and full availability of its $35 million revolving line of credit.

Year-to-date gross margin decreased to 21.4% of sales from 38.7% the prior year primarily due to a reduction in merchandise contribution combined with the effects of deleveraging resulting from the sales decline.  The year-to-date SG&A rate was 35.8% versus 31.2% last year primarily due to the effects of deleveraging and impairment charges of $7.6 million, partially offset by company-wide expense reductions and the reduction of incentive compensation.  Income tax benefit for the nine months was $22.7 million compared to an expense of $6.5 million last year.

During the third quarter ended October 31, 2020, the Company opened 16 new stores, which had leases prior to the COVID-19 pandemic and permanently closed 2 stores.  As of October 31, 2020, the Company operated 1,347 stores in 33 states, compared to 1,298 stores in 31 states as of August 3, 2019.

The Cato Corporation is a leading specialty retailer of value-priced fashion apparel and accessories operating three concepts, “Cato,” “Versona” and “It’s Fashion.”  The Company’s Cato stores offer exclusive merchandise with fashion and quality comparable to mall specialty stores at low prices every day.  The Company also offers exclusive merchandise found in its Cato stores at www.catofashions.com. Versona is a unique fashion destination offering apparel and accessories including jewelry, handbags and shoes at exceptional prices every day.  Select Versona merchandise can also be found at www.shopversona.com.  It’s Fashion offers fashion with a focus on the latest trendy styles for the entire family at low prices every day.

Statements in this press release not historical in nature
 i
ncluding, without limitation, statements regarding the Company’s expected or estimated operational and financial results and potential impact of the coronavirus are considered “forward-looking” within the meaning of The Private Securities Litigation Reform Act of 1995.  Such forward-looking statements are based on current expectations that are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those contemplated by the forward-looking statements. 
Such factors include, but are not limited to
, any actual or perceived deterioration in the conditions that drive consumer confidence and spending, including, but not limited to, prevailing social, economic, political and public health conditions and uncertainties, levels of unemployment, fuel, energy and food costs, wage rates, tax rates, interest rates, home values, consumer net worth and the availability of credit; changes in laws or regulations affecting our business including tariffs; uncertainties regarding the impact of any governmental responses to the foregoing conditions; competitive factors and pricing pressures; our ability to predict and respond to rapidly changing fashion trends and consumer demands; our ability to successfully open new stores as planned and our ability of any such new stores to grow and perform as expected; adverse weather, public health threats (including the global coronavirus (COVID-19) outbreak) or similar conditions that may affect our sales or operations; inventory risks due to shifts in market demand, including the ability to liquidate excess inventory at anticipated margins; and other factors discussed under “Risk Factors” in Part I, Item 1A  of the Company’s most recently filed annual report on Form 10-K and in other reports the Company files with or furnishes to the SEC from time to time.  The Company does not undertake to publicly update or revise the forward-looking statements even if experience or future changes make it clear that the projected results expressed or implied therein will not be realized. The Company is not responsible for any changes made to this press release by wire or Internet services.

 


THE CATO CORPORATION


CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)


FOR THE PERIODS ENDED OCTOBER 31, 2020 AND NOVEMBER 2, 2019

(Dollars in thousands, except per share data)


Quarter Ended


Nine Months Ended


October 31,


%

November 2,

%


October 31,


%

November 2,

%


2020


Sales

2019

Sales


2020


Sales

2019

Sales


REVENUES

  Retail sales


$


149,205


100.0%

$

189,357

100.0%


$


414,283


100.0%

$

627,780

100.0%

  Other revenue (principally finance,

    late fees and layaway charges)


1,586


1.1%

2,166

1.1%


5,410


1.3%

6,676

1.1%

    Total revenues


150,791


101.1%

191,523

101.1%


419,693


101.3%

634,456

101.1%


GROSS MARGIN (Memo)


39,801


26.7%

70,733

37.4%


88,545


21.4%

242,701

38.7%


COSTS AND EXPENSES, NET

  Cost of goods sold


109,404


73.3%

118,624

62.7%


325,738


78.6%

385,079

61.3%

  Selling, general and administrative


51,885


34.8%

64,681

34.2%


148,353


35.8%

196,737

31.2%

  Depreciation


3,619


2.4%

3,844

2.0%


11,113


2.7%

11,523

1.8%

  Interest and other income


(791)


-0.5%

(1,662)

-0.9%


(3,603)


-0.9%

(4,491)

-0.7%

    Cost and expenses, net


164,117


110.0%

185,487

98.0%


481,601


116.2%

588,848

93.8%

Income (Loss) Before Income Taxes


(13,326)


-8.9%

6,036

3.2%


(61,908)


-14.9%

45,608

7.3%

Income Tax (Benefit) Expense


(9,704)


-6.5%

51

0.0%


(22,698)


-5.5%

6,501

1.0%

Net Income (Loss)


$


(3,622)


-2.4%

$

5,985

3.2%


$


(39,210)


-9.5%

$

39,107

6.2%

Basic Earnings Per Share


$


(0.15)

$

0.24


$


(1.64)

$

1.59

Diluted Earnings Per Share


$


(0.15)

$

0.24


$


(1.64)

$

1.59

 


THE CATO CORPORATION


CONDENSED CONSOLIDATED BALANCE SHEETS 

(Dollars in thousands)


October 31,

February 1,


2020

2020


(Unaudited)

(Unaudited)


ASSETS

Current Assets

  Cash and cash equivalents


$


18,812

$

11,824

  Short-term investments


132,574

200,387

  Restricted cash


3,917

3,896

  Accounts receivable – net


47,725

26,088

  Merchandise inventories


84,281

115,365

  Other current assets


7,185

5,237

Total Current Assets


294,494

362,797

Property and Equipment – net


81,853

88,667

Noncurrent Deferred Income Taxes


7,464

8,636

Other Assets


22,722

24,073

Right-of-Use Assets, net


184,338

200,803

      TOTAL


$


590,871

$

684,976


LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities


$


122,489

$

136,153

Current Lease Liability


54,250

63,149

Noncurrent Liabilities


19,799

21,976

Lease Liability


138,196

147,184

Stockholders’ Equity


256,137

316,514

      TOTAL


$


590,871

$

684,976

 

Cision View original content:http://www.prnewswire.com/news-releases/cato-reports-3q-net-loss-301176882.html

SOURCE The Cato Corporation

ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease

PR Newswire

VICTORIA, BC, Nov. 19, 2020 /PRNewswire/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that it has entered into a research agreement with Genmab A/S (Nasdaq: GMAB), an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. IPA will generate novel bispecific antibody combinations using Genmab’s proprietary DuoBody® platform and IPA’s proprietary antibodies in the field of infectious disease. The development of IPA’s proprietary antibodies into DuoBody constructs enables additional, novel formulations as the Company investigates a series of combinations in parallel.

“Partnering with Genmab aligns with IPA’s mission to develop safe and effective therapies for patients, in this case, specifically pertaining to the growing demand in infectious disease,” said Dr. Jennifer Bath, Chief Executive Officer of ImmunoPrecise Antibodies. “This agreement further complements our strategy to ensure that the full potential of our infectious disease programs is realized, which includes establishing productive partnerships to increase opportunities for ideal formulations with the highest safety and efficacy profiles.”

The DuoBody technology is a proprietary platform of Genmab applied in the discovery and development of bispecific antibodies across several therapeutic areas including cancer, hemophilia, autoimmune, infectious, and central nervous system diseases. DuoBody technology has been successfully used in many Genmab internal or partnered investigational clinical therapies.

As a part of the partnership, Genmab and IPA will negotiate in good faith an agreement for the commercial use of resulting DuoBody products.

About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. The Company’s experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the clinic. ImmunoPrecise’s full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development. For further information, visit www.immunoprecise.com or contact [email protected].

Forward Looking Information

This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend”, “should” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the previous quarter ended July 31, 2020 which can be accessed at

www.sedar.com

. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE ImmunoPrecise Antibodies

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/immunoprecise-and-genmab-enter-into-a-technology-partnership-targeting-infectious-disease-301176558.html

SOURCE ImmunoPrecise Antibodies Ltd.

Yext, Inc. to Report Third Quarter FY 2021 Financial Results on December 3, 2020

PR Newswire

NEW YORK, Nov. 19, 2020 /PRNewswire/ — Yext, Inc. (NYSE: YEXT), the Search Experience Cloud company, today announced that its third quarter fiscal year 2021 results will be released on Thursday, December 3, 2020, after the close of the market. The company will host a conference call at 4:30 p.m. (ET) / 1:30 p.m. (PT) to discuss its financial results with the investment community.

A live webcast of the event will be available on the Yext Investor Relations website at http://investors.yext.com.  A live dial-in is available domestically at  (877) 883-0383 and internationally at (412) 902-6506, passcode 2822335. 

A replay will be available domestically at (877) 344-7529 or internationally at (412) 317-0088, passcode 10149775, until midnight (ET) December 10, 2020.

About Yext
The ultimate source for official answers about a business online should be the business itself. However, when consumers ask questions on company websites, too often they are left in the dark with wrong answers. Yext (NYSE: YEXT), the Search Experience Cloud, solves this problem by organizing a business’s facts so it can provide official answers to consumer questions — wherever people search. Starting with the company website, then extending across search engines and voice assistants, businesses around the world, like T-Mobile, Jaguar Land Rover, BBVA USA, and Kiehl’s — as well as organizations like the U.S. State Department and World Health Organization — trust Yext to radically improve the search experience on their websites and across the entire search ecosystem.

Yext’s mission is to help businesses and organizations around the world deliver official answers everywhere people search. Yext has been named a Best Place to Work by Fortune and Great Place to Work®, as well as a Best Workplace for Women. Yext is headquartered in New York City with offices in Amsterdam, Berlin, Chicago, Dallas, Geneva, London, Miami, Milan, Paris, San Francisco, Shanghai, Tokyo, and the Washington, D.C. area — and work-from-home offices all around the world.

CONTACT: Amanda Kontor, [email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/yext-inc-to-report-third-quarter-fy-2021-financial-results-on-december-3-2020-301176346.html

SOURCE Yext, Inc.

MIND Technology Announces Fiscal 2021 Third Quarter Earnings Release and Conference Call Schedule

PR Newswire

THE WOODLANDS, Texas, Nov. 19, 2020 /PRNewswire/ — MIND Technology, Inc. (NASDAQ: MIND) announced today that it will release financial results for its fiscal 2021 third quarter ended October 31, 2020 after the market closes on Thursday, December 3, 2020.  In conjunction with the release, the Company has scheduled a conference call, which will be broadcast live over the Internet, for Friday, December 4th at 9:00 a.m. Eastern Time / 8:00 a.m. Central Time.

What:    MIND Technology Fiscal 2021 Third Quarter Earnings Conference Call

When:   Friday, December 4, 2020 at 9:00 a.m. Eastern / 8:00 a.m. Central

How:     Live via phone — By dialing (412) 902-0030 and asking for the MIND

              Technology call at least 10 minutes prior to the start time, or

              Live over the Internet — By logging onto the web at the address below

Where:  http://mind-technology.com/

For those who cannot listen to the live call, a replay will be available through December 11, 2020 and may be accessed by dialing (201) 612-7415 and using pass code 13713498#.  Also, an archive of the webcast will be available shortly after the call at http://mind-technology.com/ for 90 days.  For more information, please contact Dennard Lascar Investor Relations at 713-529-6600 or email [email protected].

About MIND Technology

MIND Technology, Inc. provides technology to the oceanographic, hydrographic, defense, seismic and security industries.  Headquartered in The Woodlands, Texas, MIND has a global presence with key operating locations in the United States, Singapore, Malaysia, and the United Kingdom.  MIND’s worldwide Marine Technology Products segment, which includes its Seamap and Klein Marine Systems units, designs, manufactures and sells specialized, high performance, marine sonar and seismic equipment.

Contacts:


Rob Capps, Co-CEO
MIND Technology, Inc.
936-291-2277

Ken Dennard / Zach Vaughan
Dennard Lascar Investor Relations


[email protected]



713-529-6600

Cision View original content:http://www.prnewswire.com/news-releases/mind-technology-announces-fiscal-2021-third-quarter-earnings-release-and-conference-call-schedule-301176886.html

SOURCE MIND Technology, Inc.

Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002

Trial to Evaluate Ability of BP1002, Targeting Bcl-2 Protein, to Treat Refractory/Relapsed Lymphoma and Chronic Lymphocytic Leukemia Patients

HOUSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the enrollment and dosing of the first patient in a Phase 1 clinical trial evaluating the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia (CLL) patients.

BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. High expression of Bcl-2 has been correlated with adverse prognosis for patients diagnosed with relapsed CLL or with relapsed, aggressive non-Hodgkin’s lymphoma. Preclinical studies have shown BP1002 to be a potent inhibitor against the Bcl-2 target, and the Company believes that its benign safety profile should enable BP1002 combination therapy with approved agents.

A total of six evaluable patients will be treated with BP1002 monotherapy in a standard 3+3 design, with a starting dose of 20 mg/m2. The treatment cycle consists of two doses per week over four weeks, resulting in eight doses administered over twenty-eight days. The primary objectives of the study include safety and tolerability of escalating doses of BP1002, recommended Phase 2 dose of BP1002, pharmacokinetics of BP1002 and BP1002 activity on Bcl-2 expression. Secondary endpoints include several efficacy measurements of tumor response.

“This study will mark a critical step in understanding the potential benefits that BP1002 may bring to patients suffering with advanced lymphoid malignancies,” said Jorge Cortes, M.D., Director of the Georgia Cancer Center and Chairman of the Bio-Path Scientific Advisory Board. “Importantly, BP1002 activity is based on blocking the Bcl-2 messenger RNA and not the BH3 domain, as is the case with venetoclax. As a result, we believe BP1002 may provide a much-needed alternative for patients with malignancies that relapsed or are refractory to venetoclax.”

“We are delighted to initiate this first-in-human clinical study of our second drug product candidate derived from the DNAbilize platform. Given the encouraging pre-clinical data and safety profile seen to date, we are very excited to begin this study, which is expected to demonstrate safety and to show initial efficacy signals in these indications with significant unmet medical need,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings.

Ian W. Flynn, M.D. will serve as the national coordinating Principal Investigator for the Phase 1 trial. Dr. Flynn is the director of lymphoma research at the Sarah Cannon Research Institute. Other sites for the clinical trial include the Georgia Cancer Center at Augusta University and The University of Texas M.D. Anderson Cancer Center.


About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it is being evaluated in lymphoma clinical studies.

For more information, please visit the Company’s website at http://www.biopathholdings.com.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These statements are based on management’s current expectations and accordingly are subject to uncertainty and changes in circumstances. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including the impact, risks and uncertainties related to COVID-19 and actions taken by governmental authorities or others in connection therewith, Bio-Path’s ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies and the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, and such other risks which are identified in Bio-Path’s most recent Annual Report on Form 10- K, in any subsequent quarterly reports on Form 10-Q and in other reports that Bio-Path files with the Securities and Exchange Commission from time to time. These documents are available on request from Bio-Path Holdings or at www.sec.gov. Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Contact Information:

I
nvestors

Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
[email protected]   

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369



Calibre Provides Generative Exploration Program Update

VANCOUVER, British Columbia, Nov. 19, 2020 (GLOBE NEWSWIRE) — Calibre Mining Corp. (TSX: CXB; OTCQX: CXBMF) (the “Company” or “Calibre”) is pleased to provide an update on its generative exploration program that is focused on identifying near-term, organic growth opportunities to complement and leverage off the Company’s “Hub-and-Spoke” operating philosophy.

The Company began dedicating resources to its nascent generative exploration program in June 2020, with the goal of identifying resource expansion opportunities located within trucking distance of the Libertad Complex, where in excess of a million tonnes of surplus annual processing capacity exists.

Through a two-pronged strategy involving district to regional scale geologic modeling and data analytics, coupled with field reconnaissance and first pass drill testing, the Company has launched an aggressive program to systematically evaluate the broader potential of its approximately 1,200 km2 portfolio of 100%-owned mining and exploration concessions. Additionally, the Company recently applied for new mineral concessions (covering another 800 km2) that exhibit similar geologic characteristics to the bonanza-style epithermal gold systems at Limon, Libertad and Pavon.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/83543431-da19-48a6-9b6b-6eb174883ad4

Russell Ball, Chief Executive Officer of Calibre stated: “We have an incredible opportunity in front of us to deliver low-cost, organic growth when considering our ‘Hub-and-Spoke’ operating philosophy and the surplus processing capacity at Libertad. We see excellent near-mine and regional opportunities for discovery and resource growth to leverage the installed and permitted surplus processing capacity. I am encouraged by the innovative approach the team has employed to identify and evaluate new opportunities to grow the business.”

Western Epithermal Belt:
Libertad
,
Limon
and Pavon
Districts

Libertad, Limon and Pavon are situated along Nicaragua’s Western Epithermal Belt, a 350 kilometer section of a prolific belt of gold-silver mines and mineral occurrences, that extends approximately 1,500 kilometers along the length of western Central America.

The Company recently engaged GoldSpot Discoveries (“GoldSpot”) to interrogate its extensive inventory of legacy exploration and mining data with their proprietary artificial intelligence technology. As part of this initiative, GoldSpot is using its Litholens platform to apply core imaging technology to automatically examine and extract unused information from more than 300,000 metres of old core photo images to create intact, geo-referenced digital core images and corresponding geological logs. These new drill hole datasets will be integrated with their companion datasets which include geologic mapping, structural data, drill hole assays, geochemistry and geophysics to create three-dimensional targeting models and prospectivity maps.

In parallel with the Goldspot initiative, Calibre’s field reconnaissance teams commenced systematic field reconnaissance mapping and geochemical sampling to evaluate the Company’s portfolio of underexplored mineral concessions along the Western Epithermal Belt. Recent advances along this front include the identification of three new areas of prospective gold mineralization located within 50 kilometers of the Libertad mill, including:

  • Kinuma: The Kinuma concession adjoins the southern and western margin of the main Libertad concession. Four north-easterly striking zones of veining and related alteration haloes have been mapped as they extend from the eight square kilometre Cosmotillo area, a broad zone of intense silica-clay style alteration that commonly caps unexposed bonanza gold vein systems at depth. Results have been received for 279 surface rock samples with 48 of these (~15%) returning anomalous gold values (> 0.1 g/t Au), including a maximum value of 33 g/t Au.

  • Amalia
    : The Amalia concession is located approximately 35 kilometres northeast of the Libertad mill. Field reconnaissance recently delineated two new zones of epithermal style veining approximately three kilometres east of the Espinoza vein, where Calibre reported favorable results from first pass reconnaissance drilling earlier this year (see Calibre news releases dated February 11, 2020 and May 20, 2020).

    The first area covers an approximate 1 x 2.5 kilometer zone of epithermal style veining that follows a north-easterly trend. The second zone has been delineated over an area approximately 50 meters wide by 1.2 kilometers along strike. Results have been received for 133 surface rock samples, with 68 of these (~50%) returning anomalous gold values (> 0.1 g/t Au), including a maximum value of 31 g/t Au.

  • Nispero
    : The Nispero concession is located approximately 25 kilometres from the Libertad mill, adjoining the Amalia concession along its northern margin. During the third quarter (following up on a cluster of legacy stream sediment gold anomalies), two north-easterly trending zones of epithermal style veining were discovered, ranging in area from 200 meters wide by 1.2 kilometers along strike and 750 meters wide by 2.5 kilometers along strike. Results have been received for 121 surface rock samples, with 33 of these (~26%) returning anomalous gold values (> 0.1 g/t Au), including a maximum value of 57 g/t Au.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/55f54ba5-3fad-4e7d-9b1b-2243a6e11ac9

Follow-up mapping and sampling to further delineate the extent of anomalous gold mineralization and define targets for first pass drill testing in 2021 is in progress. Additionally, at Pavon the team recently initiated first-pass field reconnaissance over the broader concession beyond the Pavon Norte deposit that is currently being developed.

In 2021, the Company will be adding helicopter-borne magnetics/EM/IP geophysical surveys to its surface reconnaissance mapping and geochemical sampling program. This combination is expected to significantly enhance our ability to rapidly identify and prioritize prospective epithermal-style targets that may be partially or completely concealed below surface cover.

Eastern Borosi Project
(“EBP”)
Update

Calibre’s 100%-owned EBP comprises a 176 km2 block of exploration concessions (the “EBP block”) located in northeastern Nicaragua’s prolific “Mining Triangle” district. The EBP block covers a series of sub-parallel epithermal gold-silver vein systems that are partially exposed within a broader six-kilometre-wide structural corridor that extends along a north-easterly trend for approximately 15 kilometres.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/48419aa6-e267-4737-af10-92b22a7954e5

Previous exploration delineated gold-silver resources distributed among six deposits, which combined contain inferred mineral resources totaling 4.4 million tonnes averaging 4.93 g/t Au and 80 g/t Ag, for 701,000 ounces of contained Au and 11.36 million ounces of contained Ag (see table below). Included in this inferred resource are the Guapinol, Vancouver and Riscos de Oro deposits which host higher-grade gold resources containing 518,000 ounces of Au at 8.16 g/t Au and 4.37 million ounces of Ag at 69 g/t Ag.

E
BP
Inferred
Mineral
Resource – May 2018
Deposit
– Name and Type

Tonnage Au Ag Contained Metal
(000 ) (g/t) (g/t) Gold
(000
oz
)
Silver
(000
oz
)
Guapinol Underground 612   12.74 12 251 244
Vancouver Underground 170   8.54 15 47 82
Riscos de Oro Underground 1,184   5.73 106 218 4,047
Blag Underground 740   3.01 117 72 2,776
East Dome Underground 513   2.23 219 37 3,611
La Luna Open-Pit 1,199   1.98 16 77 601
Total 4,418   4.93 80 70
1
11,361
Inferred resources (> 4g/t Au) 1,966   8.16 69 518 4,373
Notes: 1. CIM (2014) definitions were followed for classification of Mineral Resources
  2. Mineral Resources are estimated at a cut-off grade of 2.0 g/t AuEq for resources potentially mined by underground methods and 0.42 g/t AuEq for resources potentially mined by open pit methods
  3. Gold equivalent values were calculated using the formula: AuEq (g/t) = Au (g/t) + Ag (g/t) / (101.8)
  4. Mineral Resources are estimated using a long-term gold price of US$1,500 per ounce of gold, US$23 per ounce of silver.
  5. A minimum mining width of 2.4 m was used for underground and 3 m for open pit
  6. Bulk density is 2.65 t/m3 for Blag, East Dome, Riscos De Oro, and La Luna, and 2.60 t/m3 for Guapinol and Vancouver.
  7. East Dome is included in the Blag resource model and Vancouver is included in the Guapinol resource model.
  8. Numbers may not add due to rounding.
  9. Mineral Resources that are not Mineral Reserves do not have economic viability
.
  10. For further details refer to NI 43-101 Technical Report
dated May 11, 2018 available on the company’s website and
on
SEDAR
at

www.sedar.com

.

Since acquiring IAMGOLD’s 70% interest in August (see Calibre news release datedAugust 20, 2020), the Company assembled an integrated team of independent, technical subject matter experts to complete an independent review to evaluate the potential to (i) grow the existing mineral resource inventory, and (ii) to identify new discovery opportunities on the EBP block. The initial conclusions indicate significant untested discovery potential around and along trend of all six of the known vein systems, as well as at two lesser-explored areas of prospective gold-silver mineralization within the EBP block. Opportunities identified to date are summarized below:

  • Guapinol
    and
    Vancouver: Resource expansion opportunities along two parallel, south-plunging vein structures have been identified at the high-grade Guapinol and Vancouver gold deposits.

  • Riscos
    and
    Cacao: Discrete Au-Ag (and Pb-Zn) mineralized zones at Riscos are hosted in a stockwork vein breccia body along a major north-east trending regional structure. The currently defined resource remains open laterally in both directions along strike as well as down-dip. Additional potential is recognized along the three kilometer gap between the Riscos deposit and the Cacao prospect to the southwest, as well as below surface cover along the southwest continuation of the principal structural trend.

  • Blag–E
    ast
    Dome: The Blag–East Dome area represents a large cluster of Au-Ag (and Pb-Zn) veins, the majority of which are undrilled. Near-deposit expansion potential remains untested at depth as well as among the multiple vein systems in the area.

  • La Luna: The La Luna vein system remains open along strike to the north and down dip, as well as along parallel structures lateral to the main vein. Moreover, the surface geochemical patterns suggest a possible intrusive related hydrothermal center may occur in the southern portion of the prospect.

  • Paraiso: The early-stage Paraiso prospect is located approximately five kilometers southwest and along trend from the Cacao prospect. It centers on an approximate 500 by 100 meter coincident gold-arsenic-silver geochemical soil anomaly surrounded by a halo of locally elevated copper, molybdenum, zinc and bismuth, suggestive of a possible porphyry or similar style mineral intrusive center below cover.

  • Sorpresa: The Sorpresa prospect is located in the northwestern portion of the EBP block and represents a poorly exposed Au-Ag (and Pb-Zn) vein trend that merits further surface mapping and geochemical sampling coverage to delineate additional drill targets.

Calibre
and
Rio Tinto
Exploration (“RTX”)
: Borosi Earn-In Option
and Exploration Alliance

Calibre’s relationship with RTX comprises two agreements: the Borosi Earn-In Option agreement and the strategic Exploration Alliance agreement (see Calibre news release datedFebruary 24, 2020). Together, the agreements provide RTX not only the ability to explore Calibre’s 100%-owned Borosi concessions (a 667km2   property package that adjoins Calibre’s EBP block to the northeast), but also to join Calibre in a five-year, generative exploration alliance to identify and explore prospective mineral properties.

During the second and third quarters, RTX conducted an exhaustive review of exploration data collected from a combination of sources, including Calibre’s in-house information archives, Rio Tinto’s internal global information network and various external sources. A key deliverable of this effort was the identification of six porphyry copper and copper/gold porphyry exploration prospects that have been prioritized for further surface targeting and first pass drill testing in 2021.

Additionally, we are working with RTX to finalize the scope of a district-scale, regional reconnaissance survey to identify additional prospective target areas as part of the Exploration Alliance.

Quality Assurance/Quality Control

Calibre maintains a Quality Assurance/Quality Control (“QA/QC”) program for all its exploration projects using industry best practices. Key elements of the QA/QC program include verifiable chain of custody for samples, regular insertion of certified reference standards and blanks, and duplicate check assays. Drill core is halved and shipped in sealed bags to Bureau Veritas in Managua, Nicaragua, an independent analytical services provider with global certifications for Quality Management Systems ISO 9001:2008, Environmental Management: ISO14001 and Safety Management OH SAS 18001 and AS4801. Prior to analysis, samples are prepared at Veritas’ Managua facility and then shipped to its analytical facility in Vancouver, Canada. Gold analyses are routinely performed via fire assay/AA finish methods. For greater precision of high-grade material, samples assaying 10 g/t Au or higher are re-assayed by fire assay with gravimetric finish. Analyses for silver and other elements of interest are performed via Induction Coupled Plasmaspectrometry (“ICP”).

Qualified Person

The scientific and technical data contained in this news release has been reviewed and approved by Mark A. Petersen, P.Geo., VP Exploration, and a Qualified Person as defined by NI 43-101.  

ON BEHALF OF THE BOARD


Russell Ball

Russell Ball, Chief Executive Officer

For further information, please contact:

Ryan King

Vice President, Corporate Development & IR
T: (604) 628-1012
E: [email protected]
W: www.calibremining.com


About Calibre Mining Corp.

Calibre Mining is a Canadian-listed gold mining and exploration company with two 100%-owned operating gold mines in Nicaragua. The Company is focused on sustainable operating performance and a disciplined approach to growth. Since the acquisition of the Limon, Libertad gold mines and Pavon Gold Project, Calibre has proceeded to integrate its operations into a “Hub-and-Spoke” operating philosophy, whereby the Company can take advantage of reliable infrastructure, favorable transportation costs, and multiple high-grade mill feed sources that can be processed at either Limon or Libertad, which have a combined 2.7 million tonnes of annual mill throughput capacity.


Cautionary Note Regarding Forward Looking Information

This news release includes certain

forward-looking information

and

forward-looking statements

(collectively

forward-looking statements

) within the meaning of applicable Canadian securities legislation. All statements in this news release that address events or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are statements that are not historical facts and are identified by words such as “expect”,

plan

,

anticipate

,

project

,

target

,

potential

,

schedule

,

forecast

,

budget

,

estimate

,

intend

or

believe

and similar expressions or their negative connotations, or that events or conditions

will

,

would

,

may

,

could

,

should

or

might

occur Forward-looking statements necessarily involve assumptions, risks and uncertainties, certain of which are beyond Calibre

s control
.
For a listing of
risk factors
applicable to the Company, please refer to
Calibre

s annual information form for the year ended December 31, 2019, available on www.sedar.com. This list is not exhaustive of the factors that may affect Calibre

s forward-looking statements.

Calibre

s forward-looking statements are based on the applicable assumptions and factors management considers reasonable as of the date hereof, based on the information available to management at such time. Calibre does not assume any obligation to update forward-looking statements if circumstances or management

s beliefs, expectations or opinions should change other than as required by applicable securities laws. There can be no assurance that forward-looking statements will prove to be accurate, and actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Accordingly, undue reliance should not be placed on forward-looking statements.

 



ARKO / GPM Unveils Plans for its Store Prototype of the Future


Anticipates Remodeling A


pproximately


360 Stores 



Over the Next Three to Five Years


Plans Include


Complete Store


Interior and Exterior


Redesigns, Improved Customer Experience



and Expanded Food and


Beverage


Offerings

RICHMOND, Va., Nov. 19, 2020 (GLOBE NEWSWIRE) — ARKO Holdings Ltd. (TASE: ARKO), (“Arko”), whose primary asset is a controlling stake in GPM Investments, LLC, (“GPM” or the “Company”), a rapidly growing leader in the U.S. convenience store industry, unveiled its plans for its store prototype of the future for remodels and raze and rebuilds. GPM currently anticipates that it will remodel approximately 360 of its sites in key locations across the country over the next three to five years. Arko/GPM and Haymaker Acquisition Corp. also announced today a commitment for an up to $100 million investment in convertible preferred stock from MSD Capital that will be available for growth capital and funding this remodel program.

“We have been working on this prototype over the last year and are very excited about the extensive remodel program, and the benefits it will bring to our existing customers, as well as new customers who will be drawn in by the fresh new look,” said Arie Kotler, Chief Executive Officer of Arko and GPM. “Our remodeled stores will feature an expanded offering with grab ‘n’ go prepared food, beer caves, frozen food, an enhanced drink lineup and much more. Over the past few months, we have had the opportunity to take learnings from our customers’ shopping behaviors as well as the changing consumer environment and implement key updates to our remodel program and in-store offering to provide an enhanced customer experience emphasizing the local regional brand.

Mr. Kotler continued, “We believe this remodel program will generate approximately $72 million of incremental EBITDA over the next three to five years. In addition to our other strategic initiatives, including our continued core acquisition strategy as well as synergies from the recently acquired Empire business, this aggressive remodeling program underlies our confidence in our ability to continue to drive strong and consistent growth and returns for all our stakeholders.”

This remodel program across fas mart®, E-Z Mart®, Scotchman® and the rest of the portfolio of brands, will focus on enhancing the overall customer experience and value offering as well as expanding the product assortment. Key highlights to the program include:

Enhanced in-store Experience
: The remodel program will enhance the customer experience in each store through new design, assortment, navigation, and layout, including:

  • Expanded freezers for frozen foods;
  • Expanded Grab ‘n go open air coolers for prepared foods;
  • Roller grills for hot dogs and Tornados®;
  • Hot grab n go for breakfast sandwiches and bakery items;
  • Walk-in beer caves;
  • New checkout experience;
  • Essential safety items to include hand sanitizers, pump soap, masks, gloves and wipes
  • Expanded fountain drink assortment with chewy ice;
  • Addition of Frazil™ frozen drinks to 800+ stores;
  • Expanded coolers for water, soda, energy drinks and beer; and
  • New bean to cup coffee on demand for a fresh cup all the time.

Delivery: Currently available at 20 sites, GPM is rolling out delivery via DoorDash® at 300+ more stores this year.

Illustrative
Renderings and Video of the complete re-design from the forecourt to the inside four walls can be found HERE.

About GPM and Arko:

Based in Richmond, VA, GPM was founded in 2003 with 169 stores and has grown through acquisitions to become the 7th largest convenience store chain in the United States, with, following the consummation of the Empire acquisition, 2,930 locations comprised of 1,350 company-operated stores and 1,580 dealer sites to which it supplies fuel, in 33 states and Washington D.C. GPM operates in three segments: retail, which consists of fuel and merchandise sales to retail consumers; wholesale, which supplies fuel to third-party dealers and consignment agents; and GPM Petroleum, which supplies fuel to GPM and its subsidiaries selling fuel (both in the retail and wholesale segments) as well as subwholesalers and bulk purchasers.

Arko is the controlling shareholder of GPM and, as part of the business combination with Haymaker (the “Business Combination”), the shares of Arko will be de-listed from Tel-Aviv stock exchange. At the closing of the Business Combination with Haymaker, Arko will have no material independent operating activities, income, or net assets, other than its ownership interest in GPM.

About
Haymaker:
Haymaker is a $400 million blank check company formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Haymaker’s acquisition and value creation strategy is to identify, acquire and, after its initial business combination, build a company in the consumer, retail, media, or hospitality industries. Haymaker is led by Chief Executive Officer and Executive Chairman Steven J. Heyer, President Andrew R. Heyer, Chief Financial Officer Christopher Bradley, and Senior Vice President Joseph Tonnos. For more information about Haymaker, please visit www.haymakeracquisition.com.

Additional Information and Where to Find It
ARKO Corp. filed a registration statement on Form S-4 (File No. 333-248711), which includes a prospectus with respect to ARKO Corp.’s securities to be issued in connection with the Business Combination and a proxy statement with respect to Haymaker’s stockholder meeting to vote on the Business Combination (as amended, the “Haymaker proxy statement/prospectus”), with the U.S. Securities and Exchange Commission (the “SEC”). In addition, Arko filed a proxy statement (the “Arko proxy”), which includes reference to the Haymaker proxy statement/prospectus, with the Israel Securities Authority (the “ISA”). ARKO Corp., Haymaker, GPM and Arko urge investors and other interested persons to read the Haymaker proxy statement/prospectus and the Arko proxy, as well as other documents filed with the SEC and the ISA, because these documents contain important information about the Business Combination. The Haymaker proxy statement/prospectus and other relevant materials for the Business Combination will be mailed to stockholders of Haymaker as of the record date established for voting on the Business Combination. The Haymaker proxy statement statement/prospectus can be obtained, without charge, at the SEC’s web site (http://www.sec.gov).

Participants in the Solicitation
ARKO Corp., Haymaker, Arko, GPM and their respective directors, executive officers and other members of their management and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of Haymaker stockholders in connection with the Business Combination. Investors and securityholders may obtain more detailed information regarding the names, affiliations and interests of Haymaker’s directors and officers in its Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which was filed with the SEC on March 19, 2020 and is available free of charge at the SEC’s web site at www.sec.gov.

Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Haymaker’s stockholders in connection with the Business Combination is also contained in the Haymaker proxy statement/prospectus.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of the businesses of ARKO Corp., Haymaker, Arko and GPM may differ from their actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to future performance, including projected financial information (which was not audited or reviewed by auditors), and anticipated financial impacts of the Empire acquisition or the Business Combination, the satisfaction of the closing conditions to the Business Combination, and the timing of the completion of the Business Combination. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of ARKO Corp., Haymaker, Arko and GPM, and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreements with respect to the Business Combination, (2) the outcome of any legal proceedings that may be instituted against the parties following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination, including due to failure to obtain approval of the stockholders of Haymaker or other conditions to closing; (4) the impact of the COVID-19 pandemic on (x) the parties’ ability to consummate the Business Combination and (y) the business of Arko and the combined company; (5) the receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the Business Combination; (6) the inability to obtain or maintain the listing of ARKO Corp.’s common stock on Nasdaq following the Business Combination; (7) the risk that the Business Combination disrupts current plans and operations as a result of the announcement and consummation of the Business Combination; (8) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (9) costs related to the Business Combination; (10) changes in applicable laws or regulations; (11) the demand for Arko’s and the combined company’s services together with the possibility that Arko or the combined company may be adversely affected by other economic, business, and/or competitive factors; (12) the number of shares submitted for redemption by Haymaker’s stockholders in connection with the stockholder meeting to approve the Business Combination; (13) risks and uncertainties related to Arko’s business, including, but not limited to, changes in fuel prices, the impact of competition, environmental risks, restrictions on the sale of alcohol, cigarettes and other smoking products and increases in their prices, dependency on suppliers, increases in fuel efficiency and demand for alternative fuels or electric vehicles, failure by independent outsider operators to meet their obligations, acquisition and integration risks, and currency exchange and interest rates risks; (14) failure to realize the expected benefits of the acquisition of Empire; (15) failure to promptly and effectively integrate Empire’s business; (16) the potential for unknown or inestimable liabilities related to the Empire business; and (17) other risks and uncertainties included in (x) the “Risk Factors” section of the Haymaker proxy statement/prospectus and (y) other documents filed or to be filed with the SEC by Haymaker and with the ISA by Arko. The foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. ARKO Corp., Haymaker, Arko, and GPM do not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions, or circumstances on which any such statement is based.

No Offer or Solicitation

This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the Business Combination. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Investor Contact

Chris Mandeville
Caitlin Churchill
(203) 682-8200
[email protected]

Media Contact

Keil Decker
(646) 277-1200
[email protected]



Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours

Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further A
dvance the Development of Personalised T cell Therapies to Treat Solid Tumours

– Financing includes leading US-based life science investors OrbiMed and Boxer Capital of Tavistock Group

Stevenage, UK 19 November 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced it has raised £52.7 million in an oversubscribed Series C financing. OrbiMed, Boxer Capital of Tavistock Group, and other prominent US-based, healthcare-focused institutional investors join existing investors including RA Capital, Syncona, Forbion, Invus, Perceptive Advisors and Redmile Group.

Proceeds from this financing will be used to accelerate the Company’s R&D activities and further build the clinical network to support the Company’s ongoing Phase I/IIa trials, the THETIS trial in patients with recurrent or metastatic malignant melanoma and the CHIRON trial in patients with advanced non-small cell lung cancer. Both clinical trials use the Company’s innovative personalised T cell therapy approach targeting clonal neoantigens and are currently enrolling patients with interim data expected from both studies in the first half of 2021. In addition, the financing will enable the continued build out of Achilles’ manufacturing capabilities and broaden its growing pipeline of solid tumour pre-clinical product candidates.

“Achilles has made tremendous progress since its founding in 2016, and with this financing round we are further strengthening our outstanding syndicate with more leading US healthcare investors. I am delighted with this strong support for our innovative platform, team, and ambitious development strategy,” said Dr. Iraj Ali, CEO of Achilles Therapeutics. “As we progress our two lead programmes in non-small cell lung cancer and melanoma through clinical trials, we believe that our personalised T cell therapy approach has the potential to transform how certain cancers are treated, bringing much needed novel cancer therapies to patients.”

– Ends –

Notes for Editors:

About Achilles Therapeutics

Achilles Therapeutics is a clinical stage, biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase 1/2a trials, the THETIS trial in patients with recurrent or metastatic malignant melanoma and the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC). Achilles uses DNA sequencing data from each patient, together with the proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop personalised T cell-based therapies specifically targeting those clonal neoantigens.

Achilles was founded in 2016 by lead investor Syncona Ltd and is supported by an international syndicate of life science investors including RA Capital, Forbion, Invus, Perceptive Advisors, Redmile Group, OrbiMed and Boxer Capital of Tavistock Group. For further information please visit the Company’s website at: www.achillestx.com.

Further information:

Achilles Therapeutics

Dr Iraj Ali – Chief Executive Officer
+44 (0)1438 906 906
[email protected]

Julia Wilson – Head of Communications

+44 (0)7818 430877
[email protected]

Consilium Strategic Communications

Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 (0) 203 709 5000
[email protected]

US Investor Relations – Solebury Trout

Lee Stern
+1 646-378-2922
[email protected]



QIWI Appoints Chief Financial Officer

NICOSIA, Cyprus, Nov. 19, 2020 (GLOBE NEWSWIRE) — QIWI plc (NASDAQ: QIWI) (MOEX: QIWI) (“QIWI” or the “Company”), a leading provider of next generation payment and financial services in Russia and the CIS, today announced the appointment of Pavel Korzh as Chief Financial Officer effective December 1, 2020. As Chief Financial Officer, Mr. Korzh will take over the responsibilities of interim CFO Varvara Kiseleva and report directly to CEO of the Group, Mr. Boris Kim. Ms. Varvara Kiseleva will continue to serve as Deputy CFO for Corporate Finance.

Mr. Korzh has over 20 years of experience in corporate and operational finance. He has joined QIWI in August 2020 as a CFO of QIWI Bank. Before joining QIWI, Mr Korzh worked as a CFO at Ozon, a leading E-Commerce company in Russia and Wikimart, an online marketplace. Previously he worked as a Director of Treasury and Corporate Finance and Director of Financial Reporting at CTC Media and held various positions at PricewaterhouseCoopers.

Mr. Korzh graduated from Moscow State Institute of International Relations (MGIMO University) in 1996 with a degree in International Economic Relations.

“Pavel has held several financial leadership roles prior to joining QIWI. I’m convinced that his extensive experience in finance and clear focus on delivering results will be extremely helpful to QIWI in supporting our growth and execution of our strategy,” commented Mr. Boris Kim, QIWI’s Chief Executive Officer and Director. “I am confident that his expertise will be valuable to us and I am pleased to welcome Pavel as part of our team.”

“I am looking forward to becoming a part of QIWI team and leading QIWI’s finance function to contribute to Group success as the Company develops. I like to analyze data and processes to generate ideas which could improve the economics of the business. I’m looking forward to supporting the Company in reaching its key objectives and creating value for the stakeholders,” stated Mr. Korzh.


About QIWI plc.

QIWI is a leading provider of next generation payment and financial services in Russia and the CIS. It has an integrated proprietary network that enables payment services across online, mobile and physical channels. It has deployed over 19.7 million virtual wallets, over 117,000 kiosks and terminals, and enabled merchants and customers to accept and transfer over RUB 145 billion cash and electronic payments monthly connecting over 32 million consumers using its network at least once a month. QIWI’s consumers can use cash, stored value and other electronic payment methods in order to pay for goods and services or transfer money across virtual or physical environments interchangeably.



Contact

Investor Relations
+357.25028091
[email protected]